IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx.

PURPOSE:

The purpose of this bulletin is to issue updated handbook pages that include the requirements for prior authorization and the type of information needed to evaluate the medical necessity of prescriptions for Alzheimer’s Agents submitted for prior authorization.

SCOPE:

This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program. The guidelines to determine the medical necessity of Alzheimer’s Agents will be utilized in the fee-for-service delivery system and by the MA managed care organizations (MCOs) in Physical Health HealthChoices and Community HealthChoices. Providers rendering services in the MA managed care delivery system should address any questions related to the prior authorization of Alzheimer’s Agents to the appropriate MCO.

BACKGROUND:

<table>
<thead>
<tr>
<th>Date</th>
<th>Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>*01-21-14</td>
<td>09-21-13 27-21-04 33-21-13</td>
</tr>
<tr>
<td>02-21-01</td>
<td>11-21-03 30-21-08</td>
</tr>
<tr>
<td>03-21-01</td>
<td>14-21-04 31-21-16</td>
</tr>
<tr>
<td>08-21-15</td>
<td>24-21-11 32-21-01</td>
</tr>
</tbody>
</table>

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx.
The Department of Human Services’ (Department) Pharmacy and Therapeutics (P&T) Committee reviews published peer-reviewed medical literature and recommends the following:

- Preferred or non-preferred status for new drugs in therapeutic classes already included in the Preferred Drug List (PDL);
- Changes in the status of drugs on the PDL from preferred to non-preferred and non-preferred to preferred;
- New quantity limits;
- Classes of drugs to be added to or deleted from the PDL; and
- New guidelines or revisions to existing guidelines to evaluate the medical necessity of prescriptions submitted for prior authorization.

DISCUSSION:

During the September 14, 2021, meeting, the P&T Committee recommended revisions to the guidelines to determine medical necessity of Alzheimer’s Agents to remove the requirement to prior authorize preferred Alzheimer’s Agents and to clarify the prescriptions that require prior authorization for therapeutic duplication.

The revisions to the guidelines to determine medical necessity of prescriptions for Alzheimer’s Agents submitted for prior authorization, as recommended by the P&T Committee, were subject to public review and comment and subsequently approved for implementation by the Department.

PROCEDURE:

The procedures for prescribers to request prior authorization of Alzheimer’s Agents are located in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapter related to Alzheimer’s Agents) when reviewing the prior authorization request to determine medical necessity.

As set forth in 55 Pa. Code § 1101.67(a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs that require prior authorization.

ATTACHMENTS:

Prior Authorization of Pharmaceutical Services Handbook - Updated pages

RESOURCES:

Prior Authorization of Pharmaceutical Services Handbook – SECTION I
Pharmacy Prior Authorization General Requirements
Prior Authorization of Pharmaceutical Services Handbook – SECTION II
Pharmacy Prior Authorization Guidelines
https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Clinical-Guidelines.aspx
I. Requirements for Prior Authorization of Alzheimer’s Agents

A. Prescriptions That Require Prior Authorization

Prescriptions for Alzheimer’s Agents that meet any of the following conditions must be prior authorized:

1. A non-preferred Alzheimer’s Agent. See the Preferred Drug List (PDL) for the list of preferred Alzheimer’s Agents at: https://papdl.com/preferred-drug-list.

2. An Alzheimer’s Agent with a prescribed quantity that exceeds the quantity limit. The list of drugs that are subject to quantity limits, with accompanying quantity limits, is available at: https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx.

3. An acetylcholinesterase inhibitor Alzheimer’s Agent when there is a record of a recent paid claim for another acetylcholinesterase inhibitor Alzheimer’s Agent in the Point-of-Sale On-Line Claims Adjudication System (therapeutic duplication).

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Alzheimer’s Agent, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. For a non-preferred Alzheimer’s Agent, has a history of therapeutic failure, contraindication, or intolerance of the preferred Alzheimer’s Agents; AND

2. For therapeutic duplication, one of the following:
   a. Is being titrated to or tapered from another acetylcholinesterase inhibitor Alzheimer’s Agent
   b. Has a medical reason for concomitant use of the requested medications that is supported by peer-reviewed literature or national treatment guidelines; AND

3. If a prescription for an Alzheimer’s Agent is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

January 3, 2022
(Replacing June 2, 2014)
C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Alzheimer's Agent. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.